TherapeuticsMD Inc (TXMD) Receives $14.86 Consensus PT from Analysts

TherapeuticsMD Inc (NASDAQ:TXMD) has earned a consensus rating of “Buy” from the twelve research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $14.86.

TXMD has been the subject of a number of analyst reports. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Oppenheimer reissued a “buy” rating and issued a $10.00 price target on shares of TherapeuticsMD in a report on Sunday, January 28th. BidaskClub cut TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 31st. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Thursday, February 22nd. Finally, ValuEngine cut TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday, March 2nd.

Shares of NASDAQ TXMD traded up $0.07 during trading on Monday, reaching $6.05. The company had a trading volume of 1,497,751 shares, compared to its average volume of 2,284,058. TherapeuticsMD has a twelve month low of $5.94 and a twelve month high of $6.09. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -16.35 and a beta of 1.34.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, May 3rd. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. The company had revenue of $3.77 million during the quarter, compared to analyst estimates of $4.18 million. During the same period last year, the firm earned ($0.11) earnings per share. The business’s revenue was down 5.4% compared to the same quarter last year. analysts forecast that TherapeuticsMD will post -0.39 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. MANA Advisors LLC purchased a new stake in shares of TherapeuticsMD in the fourth quarter valued at $104,000. Paloma Partners Management Co purchased a new stake in shares of TherapeuticsMD in the fourth quarter valued at $105,000. Beaumont Financial Partners LLC purchased a new stake in shares of TherapeuticsMD in the first quarter valued at $123,000. Edge Wealth Management LLC grew its position in shares of TherapeuticsMD by 2,500.0% in the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after purchasing an additional 20,000 shares during the period. Finally, Claraphi Advisory Network LLC purchased a new stake in shares of TherapeuticsMD in the fourth quarter valued at $275,000. 73.21% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply